According to the latest study from BCC Research, "The Global Influenza Market" is expected to grow from $9.0 billion in 2024 ...

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...

In an exclusive interview, Sally Susman, a pioneer in corporate comms, recounts finding out that Pfizer's COVID-19 vaccine ...

The Senate shouldn’t cut funding for programs that promote peace, stability, trade and efficiency.

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

(Reuters) -British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to ...

Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...

Amid the sultry summer months, a few signs of fall become apparent, such as the appearance of school supplies on stores ...

FDA head Marty Makary said the agency may fast-track drugs from companies that “equalize” the cost of medicines between the U ...

Respiratory syncytial virus (RSV) infections were associated with significantly increased risk for complications beyond ...

Shares of GSK rose on Thursday after the company announced it had begun shipping its seasonal flu vaccines, Fluarix and ...

The disease was found following tests on a severely emaciated doe that was euthanized and tested in early June, Andrea Korman ...